Digital therapeutics (DTx) are becoming more prominent offerings in healthcare. Questions are now arising around which stakeholders will pay for these products and how accessible they’ll be for patients.
Digital therapeutics (DTx) are an emerging category of evidence-based technologies that could disrupt drug development and disease treatment. DTx products have not hit the mainstream and will need to meet a high standard of clinical validation that separates these solutions from the sea of available digital health tools and apps on the market.
3 KEY QUESTIONS THIS REPORT WILL ANSWER
How has the pandemic advanced DTx?
Why should payers, employers, providers, and drug developers want to invest in DTx now?
What must happen next for DTx tools to become key components of how diseases are managed and treated?
WHAT’S IN THIS REPORT? How DTx solutions differ from typical digital health products and the opportunity they offer, as well as an analysis of the factors that will define success for DTx companies.
Bakar Computational Health Sciences Institute, University of California, San Francisco
Researcher
Interviewed February 24, 2022
Andy Molnar
Digital Therapeutics Alliance
CEO
Interviewed February 17, 2022
Marissa Schlueter Moore
OMERS Ventures
Health Tech Investor
Interviewed March 2, 2022
Santosh Shanbhag
Akili Interactive
CFO
Interviewed March 14, 2022
Chris Wasden
Happify Health
Head of Pharma Specialty Solutions and Corporate Strategy
Interviewed March 3, 2022
Access full deck
View a slide-show representation of this report’s key insights, where carefully vetted data is combined with industry trend analysis, included at no extra cost.
Gain access to reliable data presented in clear and intelligible displays for quick understanding and decision making on the most important topics related to your industry, included at no extra cost.
Outcomes/Evidence of Efficacy that Are Most Crucial to Making a Prescription Digital Therapeutics (PDTs) Coverage Determination According to US Payers and Employers, Summer 2021 (number of respondents)
US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)
Outcomes/Evidence of Efficacy that Are Most Crucial to Making a Prescription Digital Therapeutics (PDTs) Coverage Determination According to US Payers and Employers, Summer 2021 (number of respondents)
US Payers and Employers Who View Prescription Digital Therapeutics (PDTs) as an Effective Tool for Treating Unmet Needs in Select Diseases, Summer 2021 (% of respondents in each group)